BiotechTube
Home/iOnctura/Michael Lahn
ML

Michael Lahn

Chief Medical Officer

iOnctura

Therapeutic Areas

Oncology

iOnctura Pipeline

DrugIndicationPhase
Roginolisib (IOA-244)Oncology (unspecified)Phase 2
Cambritaxestat (IOA-289)Oncology (unspecified)Phase 2
IOA-359Oncology (unspecified)Phase 1

Leadership Team at iOnctura

CP
Catherine Pickering
Co-Founder, Chief Executive Officer
LV
Lars van der Veen
Co-Founder, Chief Scientific Officer
EH
Elizabeth Holt
Chief Business Officer
View full iOnctura profile